THER-29. NOVEL DUAL EGFR/PI3-KINASE INHIBITORS SHOW ENHANCED POTENCY, STRONGER PATHWAY SUPPRESSION AND TARGETING OF METABOLIC PROPERTIES IN PEDIATRIC AND ADULT HIGH GRADE GLIOMA MODELS THAN SINGLE KINASE INHIBITORS